Poisons List Amendment Order 2002 (TAS)

Poisons List Amendment Order 2002

I make the following order under section 15(1) of the Poisons Act 1971 .20 February 2002

judy jackson

Minister for Health and Human Services

1Short titleThis order may be cited as the Poisons List Amendment Order 2002 . 2CommencementThis order takes effect on the day on which its making is notified in the Gazette or on 1 March 2002, whichever is later. 3Principal OrderIn this order, the Poisons List Order 2001 is referred to as the Principal Order. 4Schedule 2 amended (Medicinal Poisons) Schedule 2 to the Principal Order is amended as follows: (a) by omitting item 2017 and substituting the following:

2017.  Bifonazole in preparations for dermal use, except in preparations containing 1% or less of bifonazole for the treatment of the scalp.

(b) by omitting items 2044M and 2044S ; (c) by inserting after subparagraph (iii) in paragraph (b) of item 2054 the following:

2054M.	Folic acid for human therapeutic use except –
(a) when included in Schedule 4 ; or
(b) in preparations containing 500 micrograms or less of folic acid per recommended daily dose.
2054S.	Folinic acid for human therapeutic use except –
(a) when included in Schedule 4 ; or
(b) in preparations containing 500 micrograms or less of folinic acid per recommended daily dose.

(d) by inserting after item 2094 the following:

2094M.  Minoxidil in preparations for dermal use containing 5% or less of minoxidil.

(e) by inserting after paragraph (b) in item 2098 the following:

2098M.  Nizatidine for the relief of symptoms of gastro-oesophageal reflux, in packs containing not more than 14 days’ supply.

(f) by omitting items 2114 , 2115 and 2116 and substituting the following:

2114.	Podophyllotoxin in preparations containing 0.5% or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts.
2115.	Podophyllum emodi (podophyllin) in preparations containing 10% or less of podophyllin for human use for the treatment of warts other than anogenital warts.
2116.	Podophyllum peltatum (podophyllin) in preparations containing 10% or less of podophyllin for human use for the treatment of warts other than anogenital warts.

(g) by omitting item 2127 and substituting the following:

2127.	Silver for therapeutic use except –
(a) in chewing gum each containing 5mg or less of silver per dosage unit when labelled with the statement "Overuse may stain skin or mouth"; or
(b) in solutions for human oral use containing 0.3% or less of silver when labelled with the statement "Overuse may stain skin or mouth"; or
(c) in other preparations containing 1% or less of silver.

5Schedule 3 amended (Potent Substances) Schedule 3 to the Principal Order is amended as follows: (a) by omitting item 3053 ; (b) by omitting item 3058 ; (c) by omitting items 3063 , 3064 and 3065 and substituting the following:

3063.	Podophyllotoxin in preparations containing 1% or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2 .
3064.	Podophyllum emodi (podophyllin) in preparations containing 20% or less of podophyllin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2 .
3065.	Podophyllum peltatum (podophyllin) in preparations containing 20% or less of podophyllin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2 .

(d) by omitting item 3072 and substituting the following:

3072.  Selenium in preparations for human oral use with a recommended daily dose of 100 micrograms or less of selenium, except where the sum of the organic selenium (expressed in micrograms) and half the inorganic selenium (expressed in micrograms) contained in the recommended daily dose of the preparation does not exceed 26 micrograms.

6Schedule 4 amended (Restricted Substances) Schedule 4 to the Principal Order is amended as follows: (a) by inserting after item 40191 the following:

40191M.  Bexarotene.

(b) by omitting item 40194 and substituting the following:

40194.	Bifonazole except –
(a) when included in Schedule 2 ; or
(b) in preparations containing 1% or less of bifonazole for dermal use for the treatment of the scalp.

(c) by inserting after item 40547 the following:

40547S.  Drospirenone.

(d) by omitting item 40830 and substituting the following:

40830.	Ivermectin –
(a) for human use; or
(b) for the treatment of mange in dogs.

(e) by inserting after item 40845 the following:

40845S.  Lanreotide.

(f) by inserting after item 40880 the following:

40880M.  Lopinavir.

(g) by omitting item 41004 and substituting the following:

41004.  Minoxidil except when included in Schedule 2 .

(h) by omitting item 41080 and substituting the following:

41080.  Nitrous oxide for inhalation.

(i) by omitting item 41082 and substituting the following:

41082.  Nizatidine except when included in Schedule 2 .

(j) by omitting items 41238 , 41239 and 41240 and substituting the following:

41238.	Podophyllotoxin for human use –
(a) in preparations for internal use; or
(b) in preparations for the treatment of anogenital warts; or
(c) in other preparations except when included in Schedule 2 or 3 .
41239.	Podophyllum emodi (podophyllin) for human use –
(a) in preparations for internal use; or
(b) in preparations for the treatment of anogenital warts; or
(c) in other preparations except when included in Schedule 2 or 3 .
41240.	Podophyllum peltatum (podophyllin) for human use –
(a) in preparations for internal use; or
(b) in preparations for the treatment of anogenital warts; or
(c) in other preparations except when included in Schedule 2 or 3 .

(k) by inserting after item 41331 the following:

41331S.  Reboxetine.

(l) by omitting item 41368 and substituting the following:

41368.	Selenium for therapeutic use except –
(a) when included in Schedule 3 , 6 or 7 ; or
(b) in preparations for oral human use where the sum of the organic selenium (expressed in micrograms) and half the inorganic selenium (expressed in micrograms) contained in the recommended daily dose of the preparation does not exceed 26 micrograms; or
(c) for the treatment of animals –
(i) in solid, slow-release bolus preparations each weighing 100g or more and containing 300mg or less of selenium per dosage unit; or
(ii) in other divided preparations containing 30 micrograms or less of selenium per dosage unit; or
(iii) as elemental selenium in pellets containing 100g/kg or less of selenium; or
(iv) in feeds containing 1g/tonne or less of selenium; or
(d) in preparations for topical use containing 2.5% or less of selenium sulphide.

7Schedule 6 amended (Agricultural and Industrial Poisons) Schedule 6 to the Principal Order is amended as follows: (a) by omitting items 6118 and 6119 ; (b) by omitting item 6354 and substituting the following:

6354.	Pyrithione zinc except –
(a) when included in Schedule 2 ; or
(b) in semi-solid hair preparations; or
(c) in shampoos containing 2% or less of pyrithione zinc when labelled with the statement, "Keep out of eyes" or "If in eyes, rinse well with water"; or
(d) when immobilised in solid preparations containing 0.5% or less of pyrithione zinc.

(c) by inserting after item 6387 the following:

6387E.  Tebuthiuron.

8Schedule 7 amended (Dangerous Poisons) Schedule 7 to the Principal Order is amended by omitting items 7070 and 7071 and substituting:

7070.  Demeton-O-methyl.

7071.  Demeton-S-methyl.

Displayed and numbered in accordance with the Rules Publication Act 1953.

Notified in the Gazette on 27 February 2002

This order is administered in the Department of Health and Human Services.

EXPLANATORY NOTE

(This note is not part of the order) This order amends the